Related references
Note: Only part of the references are listed.T1/T2 ratio: A quantitative sensitive marker of brain tissue integrity in multiple sclerosis
Salem Hannoun et al.
JOURNAL OF NEUROIMAGING (2022)
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis-yes
Kunio Nakamura et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No
Mark Muehlau
MULTIPLE SCLEROSIS JOURNAL (2022)
T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis - Commentary
Alex Rovira et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations
Mateus Boaventura et al.
NEUROIMAGE-CLINICAL (2022)
Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study
Monica Margoni et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2022)
Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI
Yufan Zheng et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Gray matter atrophy cannot be fully explained by white matter damage in patients with MS
Jian Zhang et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis EXPAND Secondary Analyses
Ralph H. B. Benedict et al.
NEUROLOGY (2021)
Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis
Marijn Huiskamp et al.
NEUROLOGY (2021)
Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis
Maria A. Rocca et al.
NEUROLOGY (2021)
A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes
Karen K. Chung et al.
ANNALS OF NEUROLOGY (2020)
Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis
D. Pareto et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2020)
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Jeremy Chataway et al.
LANCET NEUROLOGY (2020)
Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS
Muthuraman Muthuraman et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
White matter lesion location correlates with disability in relapsing multiple sclerosis
Laura Gaetano et al.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2020)
Brain mapping in multiple sclerosis: Lessons learned about the human brain
Massimo Filippi et al.
NEUROIMAGE (2019)
Cognitive reserve, cognition, and regional brain damage in MS: A 2-year longitudinal study
Maria Assunta Rocca et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Cognitive reserve, cognition, and regional brain damage in MS: A 2-year longitudinal study
Maria Assunta Rocca et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis
Graham Cooper et al.
FRONTIERS IN NEUROLOGY (2019)
Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease
Wiesje Pelkmans et al.
HUMAN BRAIN MAPPING (2019)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Carmen Tur et al.
NATURE REVIEWS NEUROLOGY (2018)
Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study
Niels Bergsland et al.
NEUROIMAGE-CLINICAL (2018)
Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
Konstantinos Kamnitsas et al.
MEDICAL IMAGE ANALYSIS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipoic acid in secondary progressive MS A randomized controlled pilot trial
Rebecca Spain et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis
Kunio Nakamura et al.
ANNALS OF NEUROLOGY (2017)
Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging
Ruthger Righart et al.
ANNALS OF NEUROLOGY (2017)
Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant
Martijn D. Steenwijk et al.
BRAIN (2016)
What lies beneath grey matter atrophy in multiple sclerosis?
Declan T. Chard et al.
BRAIN (2016)
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis
K. A. Meijer et al.
NEUROIMAGE-CLINICAL (2016)
Geodesic Information Flows: Spatially-Variant Graphs and Their Application to Segmentation and Fusion
M. Jorge Cardoso et al.
IEEE TRANSACTIONS ON MEDICAL IMAGING (2015)
What drives MRI-measured cortical atrophy in multiple sclerosis?
V. Popescu et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
What drives MRI-measured cortical atrophy in multiple sclerosis?
V. Popescu et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Whole brain myelin mapping using T1-and T2-weighted MR imaging data
Marco Ganzetti et al.
FRONTIERS IN HUMAN NEUROSCIENCE (2014)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cognition in multiple sclerosis
Dawn W. Langdon
CURRENT OPINION IN NEUROLOGY (2011)
Mapping Human Cortical Areas In Vivo Based on Myelin Content as Revealed by T1- and T2-Weighted MRI
Matthew F. Glasser et al.
JOURNAL OF NEUROSCIENCE (2011)
N4ITK: Improved N3 Bias Correction
Nicholas J. Tustison et al.
IEEE TRANSACTIONS ON MEDICAL IMAGING (2010)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N. De Stefano et al.
NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
Gray matter atrophy in multiple sclerosis: A longitudinal study
Elizabeth Fisher et al.
ANNALS OF NEUROLOGY (2008)
Independent component analysis of fMRI group studies by self-organizing clustering
F Esposito et al.
NEUROIMAGE (2005)
The clinico-radiological paradox in multiple sclerosis revisited
F Barkhof
CURRENT OPINION IN NEUROLOGY (2002)